Recurrence pattern in the presence of hepatosteatosis in breast cancer: does it facilitate liver metastasis?

• Published in: Future oncology (London, England) Vol. 16; no. 18; pp. 1257 - 1267
• Main Authors: Kus, Tulay, Cinkir, Havva Yesil, Aktas, Gokmen, Abali, Huseyin
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.06.2020
• Subjects: Adult; Biomarkers, Tumor; Breast cancer; Breast Neoplasms - complications; Breast Neoplasms - etiology; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Cancer therapies; Chemotherapy; Diabetes; Fatty Liver - complications; Female; Follow-Up Studies; hepatosteatosis; Humans; Kaplan-Meier Estimate; Liver cancer; Liver Neoplasms - secondary; Medical prognosis; Metabolic syndrome; Metastasis; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Obesity; prediction; Prognosis; recurrence; remission; Retrospective Studies; recurrence; prediction; breast cancer; hepatosteatosis; remission
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2019-0634

We aimed to investigate the impact of hepatosteatosis (HS) severity on the recurrence pattern of breast cancer and to clarify whether HS causes affinity to recurrence with liver metastasis. The median follow-up was 80.0 (4–217) months and the mean age was 47.9 ± 11.3 years. Among all, 181 (39.9%) patients were diagnosed with grades 2 and 3 HS. Of total, 158 (34.8%) patients have experienced recurrence. While higher degree of HS was more common in patients presented with liver recurrence (odds ratio; 95% CI: 2.50; 1.27–4.92; p = 0.007), it was lesser in those with other metastatic sites (all were >0.05). Liver-recurrence-free survival was significantly worse in the group with higher degree of HS (hazard ratio; 95% CI: 2.46; 1.4–4.3; p = 0.002) together with younger age (hazard ratio; 95% CI: 2.44; 1.4–4.3; p = 0.002) in multivariate analysis. HS might have produced an affinity for liver metastasis in common types of breast cancer patients in remission independent from metabolic disorders or clinicopathologic features.